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CLINICAL USESOF CISPLATINUM FOR UROLOGICAL CANCER
                     Noriaki SAiTo， Hiroyuki’KAWAHARA，
                    Manabu SuzuKi and Hiroyoshi TANAKA
Fr・m the DePartment ・f伽1・g“（Direc彦。鍔PrOf． H． Tanakaノ，・Kawasaki Me伽I Sch・・1．0吻，ama，ノbPan
   Cisplatinum was usied in the treatment of urological cancer．
   27 patients of this study consisted of 6 cases of bladder cancer， 7 cases of prostatic cancer， 4 cases
ofnon－seminomatous testicular tumor and 3 cases ofrenal cell cancer． They had all objectively measur－
able or evaluable lesions of malignant disease．
   After 1，000 ml of saline was injected， 1．0－2．O mg／kg of Cisplatinum diluted in 500 ml of 50／．
glucose including KCL 20 mEqll， Mannitol 50 mi and Droperidol 3．O m｝ was administrated in S・
hours by single dose or multiple dose regimen combined with vincristine 1．．O mg and adriamycin 30 mg’
or bleomycin 30 mg．
   Complete response was achieved in one case of bladder cancer， partial response was done in S
cases of bladder cancer， 4 cases of prostatic cancer， and all cases of non－seminomatous testicular tumor．
   But no response was obtained in ail case of renal’cell cancer．
   As to side effects， nephrotoxicity was appeared in all cases but only two cases had to discontinue
the administration．
   Myelosuppression wa＄ shown in 2 ． cases， which was considered to be induced by vincristine or
adriamycin， rather than aisplatinum．
   Hypomagnesemia and extrapyramidal tract sign were found in one case， which was made attention．
   Nausea and vomiting were complained of in all cases． The complaints were able to be supressed
by using the Droperidol．
               緒．  言
  cis－diammiqedichl・r・platinum（以下cisplatinum＞
本剤．は．米国．で開．発．．さ．れ1一一3）1．．．泌尿器科領域ではおもに
      コ                                            コnon－semmomatous testicular tumorに対して用いら．



















泌尿紀要 28巻 特集号 1982年
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Renal pelvic ca． 1
tota1 27
投与前，生食1，000 mlの補液をした後， cisplatinum














































Table 2． Bladder ca． （therapeutic purpose）
晦沼南㈱・繍R・α脚・譜櫨㎎，・ing1・Combination
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Table 4． Prostatic ca．
M． itoe Fbtho． ftix theraov1b鳳dose      Single
of coDP （mg）
Combination
1 75 Moderatety C＋E＋R
2 5‘ FborlyC＋E＋R＋5Fu
































































Fig． 2． Bone X－P of case No． 4
Fig． 3． Bone scintigram of case No． 4
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Table 5． Response （Prostatic ca．）
晦瀦欝襯ぽ脚 KcrnofSky Response1 so o／． Lt o’亙LB ・←  、  ゆ 。－c’ PR
2  30％ゆN O 闇●b   ■●・   ゆ 。一 o NC・
3 40 o／． 一 ”M1L．． o 口し  、  ㌔L o－o NC
4 eo Olo－pt！Lbloo Ol．ゆ   口■）  、 1－B PR
5 co Ole za2M 90“leN  X  N o－c PR
6 70 010 za eo el．■レ  ゆ  、 o一 c PR
7 8001e 一21M1L．” 80 ele
rの・  ◆   ■し 。－o NC
Table 6． Testicular tumor








     Embryona1
5 25 cell ca．
     （＋c＋s）
Lumbor L．N．300 ・一・ i躍聾〉・PR
4 76 Hisl’iocytic      lymptomaLumbar spine15・翫・1艦縣・PR






















Table 7． Side effect
泌尿紀要 28巻 特集号 1982年
1．Nephro士oxiclty；Cr・cleqronce．（ml／minl｝
   Severe ： 一50 一一一一一一一一T 一・ 一・一一一一一一一 4／27  （
   Mild ： 50一一60 一一一一一一一一一一一一・一一一 j 1／27
   Free ： 60一一 一一一・一・一一一一一一一一一一一一一一一・一 ［2／27
2． Myelosupression ； RBC， WBC
   Severe ： 一一200， 一一1500一一一一一一一一一一 4／27  （
   Mild ：200一・soO，［500一一5000一一一一19／27
   Free ： 300 一’ ，5000一 一一一一一 一一 4f27
5． Hypomagnesemio；（mEq／l）
   Severe ： 一一1．O一一一一一一一一一一一一一一一一 1／2［  （
   Mild 二1．O・一．L5一一一一一一一一一一一一一一一一一［4／21
   Free ： LsN一一一一一一一一一一一一一一一一一一一 6／2［
4． Ototoxicity ； 一一一一一一一一一一一一一一一一一一一・一一一一 O／l2
5． Nausea， Vomiting ；
   Severe ： 一一一一一一一一一一一一一一一一一一一一 15／27  （
   Mild ：一一一一一一一一一一一一一一一一一一一一一一一一一8／27
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